Could a popular Weight-Loss drug help obese women beat uterine precancer without surgery?
NCT ID NCT07107334
First seen Jan 04, 2026 · Last updated May 05, 2026 · Updated 20 times
Summary
This pilot study tests whether adding a GLP-1RA weight-loss drug (like semaglutide) to a hormonal IUD can reverse precancerous changes in the uterus lining of obese women. About 20 women who are not good candidates for hysterectomy or wish to preserve fertility will be followed for up to 12 months. The goal is to see if the combination can clear the precancer, potentially avoiding major surgery or enabling pregnancy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Florida
RECRUITINGGainesville, Florida, 32608, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.